Last reviewed · How we verify

Moxifloxacin and Dexamethasone combined — Competitive Intelligence Brief

Moxifloxacin and Dexamethasone combined (Moxifloxacin and Dexamethasone combined) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic + Corticosteroid combination. Area: Infectious Disease / Ophthalmology.

phase 3 Fluoroquinolone antibiotic + Corticosteroid combination Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone) Infectious Disease / Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Moxifloxacin and Dexamethasone combined (Moxifloxacin and Dexamethasone combined) — Federal University of São Paulo. Moxifloxacin (a fluoroquinolone antibiotic) inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone (a corticosteroid) suppresses inflammation and immune response.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Moxifloxacin and Dexamethasone combined TARGET Moxifloxacin and Dexamethasone combined Federal University of São Paulo phase 3 Fluoroquinolone antibiotic + Corticosteroid combination Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone)
moxifloxacin / dexamethasone moxifloxacin / dexamethasone Federal University of São Paulo marketed Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor
Levofloxacin + dexamethasone followed by dexamethasone Levofloxacin + dexamethasone followed by dexamethasone NTC srl phase 3 Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase, topoisomerase IV (levofloxacin); glucocorticoid receptor (dexamethasone)
Ciprofloxacin HCl and Hydrocortisone Ciprofloxacin HCl and Hydrocortisone Farmoquimica S.A. phase 3 Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor
Moxifloxacin / Dexamethasone Ophthalmic Solution Moxifloxacin / Dexamethasone Ophthalmic Solution Laboratorios Sophia S.A de C.V. phase 3 Fluoroquinolone antibiotic + Corticosteroid combination Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic + Corticosteroid combination class)

  1. Federal University of São Paulo · 1 drug in this class
  2. Laboratorios Sophia S.A de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Moxifloxacin and Dexamethasone combined — Competitive Intelligence Brief. https://druglandscape.com/ci/moxifloxacin-and-dexamethasone-combined. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: